マルタ - 英語 - Medicines Authority

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - mannitol - solution for infusion - mannitol 200 mg/l - blood substitutes and perfusion solutions

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 10 per cent - mannitol

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 15 %w/v - mannitol

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

icu medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema; - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) . no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to mat

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

henry schein, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)]. - active intracranial bleeding except during craniotomy. 8.1 pregnancy risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data).no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 20 percent weight/volume - solutions producing osmotic diuresis; mannitol

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - mannitol - solution for infusion - 15 percent weight/volume - solutions producing osmotic diuresis; mannitol

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

schwabe north america, inc - pelargonium sidoides root (unii: h6j53hex8e) (pelargonium sidoides root - unii:h6j53hex8e) - pelargonium sidoides root 1 [hp_x]

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

fresenius kabi usa, llc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection, usp is indicated for the following therapeutic uses: • the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established.  • the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass.  • the reduction of elevated intraocular pressure when it cannot be lowered by other means.  • the promotion of urinary excretion of toxic substances. mannitol solution, 2.5% is indicated as an irrigation solution in transurethral prostatic resection or other transurethral surgical procedures. • well established anuria due to severe renal disease.  • severe pulmonary congestion or frank pulmonary edema.  • active intracranial bleeding except during craniotomy.  • severe dehydration.  • progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia.  • progressive heart failure or pulmonary congestion after mannitol therapy

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hospira, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol intravenous (mannitol injection, usp) is indicated for the following purposes in adults and pediatric patients. - reduction of intracranial pressure and brain mass. - reduction of high intraocular pressure when the pressure cannot be lowered by other means. measurement of glomerular filtration rate. - well established anuria due to severe renal disease. - severe pulmonary congestion or frank pulmonary edema. - active intracranial bleeding except during craniotomy. - severe dehydration. - progressive heart failure or pulmonary congestion after institution of mannitol therapy. - do not administer to patients with a known hypersensitivity to mannitol. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will dimin